Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.
作者信息
Shah Nirav N, Johnson Bryon D, Fenske Timothy S, Raj Renju V, Hari Parameswaran
机构信息
Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI; and.
Avera Hematology and Bone Marrow Transplant, Avera McKennan Hospital and University Health Center, Sioux Falls, SD.
出版信息
Blood Adv. 2020 May 26;4(10):2119-2122. doi: 10.1182/bloodadvances.2020001626.
Abstract
摘要
相似文献
1
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.鞘内化疗用于治疗类固醇难治性CAR T细胞相关神经毒性综合征
Blood Adv. 2020 May 26;4(10):2119-2122. doi: 10.1182/bloodadvances.2020001626.
2
Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome.鞘内化疗作为治疗类固醇难治性免疫效应细胞相关性神经毒性综合征的一种潜在方法。
Anticancer Res. 2022 Aug;42(8):3853-3856. doi: 10.21873/anticanres.15876.
3
Neurological Complications of CAR T Cell Therapy.嵌合抗原受体 T 细胞疗法的神经系统并发症。
Curr Oncol Rep. 2020 Jul 1;22(8):83. doi: 10.1007/s11912-020-00935-6.
4
Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.鞘内注射氢化可的松治疗儿童和青年 CAR T 细胞免疫效应细胞相关性神经毒性综合征。
Pediatr Blood Cancer. 2024 Jan;71(1):e30741. doi: 10.1002/pbc.30741. Epub 2023 Oct 27.
5
Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).口吃作为嵌合抗原受体T细胞相关脑病综合征（CRES）的首发症状。
J Cancer Res Clin Oncol. 2019 Jul;145(7):1917-1918. doi: 10.1007/s00432-018-2818-y. Epub 2018 Dec 11.
6
A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.嵌合抗原受体T细胞免疫疗法相关神经并发症的简要综述
Neurol Clin. 2020 Nov;38(4):953-963. doi: 10.1016/j.ncl.2020.08.001. Epub 2020 Sep 12.
7
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.嵌合抗原受体 T 细胞过继免疫治疗后的神经毒性的临床表现、治疗和生物标志物。
Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
8
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.早期鞘内治疗以管理高等级免疫效应细胞相关性神经毒性综合征。
JAMA Oncol. 2022 May 1;8(5):773-775. doi: 10.1001/jamaoncol.2022.0070.
9
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤：疗效、毒性和比较嵌合抗原受体产品。
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
10
Targeting TAK1 in microglia to treat CAR T cell neurotoxicity.靶向小胶质细胞中的TAK1以治疗CAR T细胞神经毒性。
Nat Cancer. 2024 Aug;5(8):1143-1144. doi: 10.1038/s43018-024-00765-6.
引用本文的文献
1
[Chimeric antigen receptor T-cells for patients with hematologic malignancies].用于血液系统恶性肿瘤患者的嵌合抗原受体T细胞
Z Rheumatol. 2025 Sep 4. doi: 10.1007/s00393-025-01703-2.
2
Neurological complications of CAR T cell therapy for cancers.嵌合抗原受体（CAR）T细胞疗法治疗癌症的神经并发症
Nat Rev Neurol. 2025 Jun 25. doi: 10.1038/s41582-025-01112-8.
3
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.嵌合抗原受体（CAR）T细胞疗法用于原发性骨肿瘤的疗效及适用性：当前证据的全面综述
J Bone Oncol. 2024 Sep 22;48:100635. doi: 10.1016/j.jbo.2024.100635. eCollection 2024 Oct.
4
Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity.鞘内化疗作为嵌合抗原受体T细胞（CAR T）疗法相关神经毒性的治疗方法。
Bone Marrow Transplant. 2024 Dec;59(12):1783-1785. doi: 10.1038/s41409-024-02417-w. Epub 2024 Sep 19.
5
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.乘风破浪：CAR-T 细胞疗法中细胞因子相关毒性的管理。
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.
6
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
7
Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.病例报告：一线鞘内化疗（甲氨蝶呤、阿糖胞苷和地塞米松）后，IV 级 ICANS 迅速缓解。
Front Immunol. 2024 May 3;15:1380451. doi: 10.3389/fimmu.2024.1380451. eCollection 2024.
8
Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.嵌合抗原受体 T 细胞在成人中的毒性、重症监护管理和结局：最新进展。
Crit Care. 2024 Mar 5;28(1):69. doi: 10.1186/s13054-024-04851-0.
9
Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia.嵌合抗原受体T细胞疗法治疗急性白血病
Blood Cell Ther. 2023 Nov 25;6(4):145-150. doi: 10.31547/bct-2023-028.
10
Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.鞘内注射氢化可的松治疗儿童和青年 CAR T 细胞免疫效应细胞相关性神经毒性综合征。
Pediatr Blood Cancer. 2024 Jan;71(1):e30741. doi: 10.1002/pbc.30741. Epub 2023 Oct 27.
本文引用的文献
1
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.优化嵌合抗原受体 T 细胞疗法治疗成人急性淋巴细胞白血病。
J Clin Oncol. 2020 Feb 10;38(5):415-422. doi: 10.1200/JCO.19.01892. Epub 2019 Dec 9.
2
CAR-T-cell neurotoxicity: hope is on the horizon.嵌合抗原受体T细胞神经毒性：曙光在前。
Blood. 2019 May 16;133(20):2114-2116. doi: 10.1182/blood-2019-03-900985.
3
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.嵌合抗原受体 T 细胞过继免疫治疗后的神经毒性的临床表现、治疗和生物标志物。
Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
4
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.嵌合抗原受体 T 细胞相关神经毒性：机制、临床病理相关性及未来方向。
J Natl Cancer Inst. 2019 Jul 1;111(7):646-654. doi: 10.1093/jnci/djz017.
5
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
6
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.与 B 细胞急性淋巴细胞白血病患者的 CAR T 细胞治疗相关的神经毒性的临床和生物学相关性。
Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.
7
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.单核细胞衍生的白细胞介素-1 和白细胞介素-6 对于 CAR T 细胞引起的细胞因子释放综合征和神经毒性是有差异需求的。
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
8
Fludarabine and neurotoxicity in engineered T-cell therapy.氟达拉滨与基因工程 T 细胞治疗的神经毒性。
Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7.
9
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.与嵌合抗原受体T细胞疗法相关的细胞因子释放综合征和神经毒性的生物标志物。
Biomark Res. 2018 Jan 22;6:4. doi: 10.1186/s40364-018-0116-0. eCollection 2018.
10
JCAR015 in ALL: A Root-Cause Investigation.急性淋巴细胞白血病中JCAR015的根本原因调查。
Cancer Discov. 2018 Jan;8(1):4-5. doi: 10.1158/2159-8290.CD-NB2017-169. Epub 2017 Dec 5.
Zotero 插件